pneumonia
cap
singl
common
caus
death
among
children
worldwid
lead
caus
although
bodi
knowledg
epidemiolog
etiolog
microbiolog
pathophysiolog
cap
expand
last
decad
basic
patient
manag
question
remain
larg
unansw
fact
confront
feverish
child
respiratori
symptom
singl
import
manag
question
whether
start
antibiot
translat
confid
treat
physician
child
question
bacteri
lower
respiratori
tract
although
epidemiolog
research
repeatedli
point
larg
major
lower
respiratori
infect
pediatr
patient
caus
physician
often
lack
tool
reliabl
discrimin
bacteri
viral
larg
percentag
children
present
respiratori
symptom
fever
ultim
administ
absenc
certainti
regard
cap
etiolog
thu
prompt
overtreat
consequ
increas
emerg
bacteri
resist
metabolom
newest
branch
system
biolog
approach
biomed
aim
provid
unabridg
descript
qualit
quantit
metabolit
ie
molecul
molecular
weight
less
da
found
human
biofluid
tissu
given
time
word
aim
defin
particular
metabol
signatur
fingerprint
character
diseas
state
power
analyt
tool
use
amass
larg
amount
data
analyz
appli
complex
question
biolog
particular
metabolom
provid
comprehens
overview
diseas
pathophysiolog
identifi
new
biomark
use
diagnost
point
potenti
therapeut
target
consid
search
new
drug
present
exploratori
investig
approach
base
untarget
metabolom
appli
pediatr
cap
pcap
effort
improv
diagnosi
clinic
manag
common
childhood
infect
specif
studi
aim
elucid
whether
specif
metabol
signatur
differenti
pneumococc
viral
pcap
exploratori
work
multicent
prospect
studi
particip
enrol
three
differ
pediatr
center
padua
pediatr
emerg
room
depart
women
children
health
padua
univers
hospit
treviso
pediatr
emerg
room
pediatr
ward
santa
maria
di
ca
foncello
hospit
milan
depart
matern
pediatr
scienc
pediatr
ward
regina
elena
hospit
septemb
januari
studi
approv
center
institut
ethic
committe
written
inform
consent
sign
parent
requir
child
includ
studi
children
age
year
older
child
written
inform
assent
also
requir
case
elig
studi
hospit
children
less
year
age
diagnosi
moder
sever
pneumonia
diagnosi
cap
base
clinic
present
presenc
fever
symptom
suggest
acut
respiratori
ill
defin
new
cough
sputum
product
chest
pain
dyspnea
tachypnea
abnorm
lung
examin
chest
chest
evalu
blind
radiologist
studi
particip
decis
admit
child
hospit
cap
made
attend
physician
emerg
depart
increas
specif
find
reduc
role
confound
variabl
three
exclus
criteria
strictli
appli
concern
infant
ie
children
year
age
avoid
diagnost
overlap
pneumonia
bronchiol
children
previou
diagnosi
chronic
diseas
hiv
asthma
immunodefici
chd
reduc
pathophysiolog
heterogen
cap
case
children
given
oral
inject
antibiot
therapi
hour
preced
enrol
avoid
case
partial
treat
pneumonia
relat
pathophysiolog
profil
differ
lung
infect
devoid
treatment
pharmacolog
treatment
recruit
subject
monitor
hospit
evalu
potenti
confound
effect
find
urin
sampl
least
ml
collect
pneumonia
patient
within
hour
enrol
precaut
taken
minim
sampl
variabl
analysi
collect
sampl
store
see
supplementari
materi
detail
enrol
deep
nasal
swab
whole
blood
sampl
collect
patient
sampl
store
ship
dri
ice
laboratori
pediatr
care
unit
univers
milan
nasal
swab
test
polymeras
chain
reaction
pcr
target
differ
respiratori
virus
influenza
ab
viru
parainfluenza
viru
coronaviru
human
metapneumoviru
human
rhinoviru
enteroviru
respiratori
syncyti
viru
adenoviru
human
bocaviru
pcr
target
streptococcu
pneumonia
plasma
procalcitonin
pct
concentr
also
measur
patient
within
hour
hospit
detail
see
supplementari
materi
algorithm
combin
microbiolog
inform
obtain
pcr
assay
pct
level
use
ascertain
pneumonia
etiolog
subsequ
metabolom
three
variabl
consid
sequenti
presenc
absenc
respiratori
virus
reveal
multiplex
pcr
assay
presenc
absenc
pneumonia
pcr
assay
pct
cutoff
ngml
use
algorithm
viral
etiolog
assum
presenc
respiratori
virus
absenc
pneumonia
pct
ngml
pneumococc
etiolog
assum
absenc
respiratori
virus
presenc
pneumonia
pct
ngml
case
fall
either
categori
label
undetermin
includ
subsequ
analysi
strategi
appli
obtain
pure
group
metabolom
investig
limit
number
case
ie
pneumonia
carrier
pneumonia
avoid
confound
due
case
ie
bacteri
infect
superimpos
viral
one
may
peculiar
addit
effect
patient
metabolom
raw
data
convert
two
data
set
markerlynx
softwar
water
corpor
rtmass
variabl
filter
accord
number
miss
valu
input
miss
valu
data
underw
probabilist
quotient
normal
mean
center
multivari
data
analysi
conduct
base
project
method
univari
data
analysi
base
test
fals
discoveri
rate
correct
receiv
oper
characterist
curv
analysi
describ
area
curv
auc
specif
exploratori
data
analysi
perform
use
princip
compon
analysi
pca
project
latent
structur
discrimin
analysi
base
variabl
influenc
project
select
appli
identifi
differ
group
investig
stabil
select
base
sampl
use
highlight
subset
relev
variabl
character
two
group
investig
estim
predict
power
model
explain
relev
variabl
highlight
multivari
data
analysi
merg
obtain
univari
data
analysi
possibl
effect
corticosteroid
treatment
relev
variabl
investig
posteriori
divid
accordingli
children
subgroup
appli
analysi
varianc
anova
follow
bonferroni
correct
variabl
annot
search
human
metabolom
databas
metlin
metabolit
databas
see
supplementari
materi
detail
patient
accru
end
enrol
period
use
propos
algorithm
patient
classifi
pcap
viral
etiolog
vrl
pcap
pneumococc
etiolog
pnc
patient
classifi
pcap
undetermin
etiolog
case
case
inconsist
result
pct
measur
pcr
analysi
exclud
subclass
analysi
tabl
contain
clinic
demograph
characterist
patient
includ
final
set
statist
data
analysi
patient
treat
accord
local
protocol
cephalosporin
ceftriaxon
cefotaxim
plu
macrolid
clarithromycin
azithromycin
base
demograph
clinic
consider
oral
parenter
steroid
betamethason
methylprednisolon
also
administ
patient
vrl
group
none
pnc
group
differ
treatment
due
viral
pneumonia
frequent
associ
wheez
especi
younger
patient
therefor
treat
steroid
preliminari
exploratori
pca
data
group
reveal
outlier
differ
metabol
profil
urin
collect
patient
vrl
group
patient
pnc
group
investig
use
stabil
select
reliabl
model
obtain
prove
capabl
distinguish
two
group
specif
neg
ioniz
dataset
model
obtain
show
compon
auc
p
auc
sevenfold
full
p
median
aucpr
calcul
stabil
select
fifth
percentil
posit
ioniz
dataset
figur
compon
auc
p
auc
sevenfold
full
p
median
aucpr
fifth
percentil
figur
show
scatter
plot
score
obtain
two
model
variabl
identifi
stabil
select
merg
select
univari
data
analysi
obtain
set
variabl
see
tabl
supplementari
materi
basi
anova
bonferroni
correct
find
effect
corticosteroid
treatment
select
relev
variabl
search
avail
onlin
metabolit
databas
gener
put
identif
variabl
tabl
metabolom
power
method
analyz
global
metabol
profil
biofluid
appli
approach
compar
children
carri
lung
infect
pnc
vrl
etiolog
present
studi
show
differ
type
lung
infect
affect
children
metabolom
differ
way
opportun
offer
oppos
diagnost
field
infecti
diseas
object
increas
omic
scienc
enabl
thorough
assess
host
respons
given
set
environment
andor
clinic
condit
thu
provid
uniqu
opportun
uncov
diagnost
biomark
biolog
pathway
infecti
diseas
may
pave
way
person
therapi
date
hand
publish
studi
examin
potenti
metabolom
analysi
appli
success
highlight
remark
opportun
afford
analyt
tool
particular
metabolom
analysi
prove
capabl
discrimin
differ
pneumonia
etiolog
adult
slupski
et
found
pneumococc
pneumonia
metabolit
fingerprint
clearli
distinguish
bacteri
pneumonia
etiolog
viral
pneumonia
banoei
et
replic
result
show
pneumonia
gener
differ
plasma
metabol
profil
bacteri
pneumonia
although
metabolom
analys
focus
pediatr
cap
far
limit
adamko
et
demonstr
metabolom
discrimin
respiratori
tract
infect
caus
respiratori
syncyti
viru
bacteri
infect
metabolit
belong
adren
steroid
synthesi
degrad
pathway
promin
among
discrimin
etiolog
cap
sampl
particular
urin
sampl
pneumococc
case
show
rel
increas
concentr
precursor
adren
steroid
androstenedion
testosteron
precursor
pregnanediol
deriv
progesteron
catabolit
ie
tetrahydrocortison
rel
increas
concentr
also
note
deriv
cortisol
synthes
zona
fasciculata
hydroxylas
physiolog
condit
pattern
metabolit
consist
global
increas
adren
cortex
activ
driven
stimul
hpa
regul
hpa
axi
bacteri
infect
involv
complex
interact
neuroendocrin
immun
system
still
fulli
cortisol
biosynthesi
degrad
crucial
host
respons
mechan
event
sever
infect
mani
studi
examin
role
cortisol
plasma
level
indic
cap
studi
offer
new
evid
pathophysiolog
hpa
axi
cours
pcap
show
chang
adren
steroid
metabol
occur
even
rel
mild
case
cap
sinc
none
patient
enrol
studi
admit
intens
care
unit
develop
sepsi
second
class
compound
relev
studi
amino
acid
deriv
gener
speak
plasma
concentr
amino
acid
disrupt
cours
sever
bacteri
infect
sepsi
greater
chang
correspond
wors
prognosi
term
particular
found
signific
differ
rel
concentr
leucin
urocan
acid
first
intermedi
histidin
degrad
pathway
phenyl
acet
acid
phenylalanin
deriv
promot
activ
polymorphonuclear
leukocyt
pmnl
oxid
burst
phagocytosi
reduc
pmnl
apoptot
cell
pleural
fluid
concentr
phenylalanin
rise
children
pneumonia
pleural
probabl
consequ
aggress
metabol
activ
amino
acid
biosynthesi
induc
pneumonia
replic
cyclic
guanosin
monophosph
cgmp
next
signific
molecul
emerg
analysi
mediat
mani
proinflammatori
function
nitric
oxid
receptor
ligand
induc
express
cgmp
increas
activ
synthetas
fact
endotoxin
infus
healthi
volunt
shown
rais
exhal
cgmp
plasma
bacteria
may
also
increas
synthesi
cgmp
produc
studi
corrobor
previou
report
provid
evid
plausibl
use
metabolit
diagnost
marker
bacteri
infect
anoth
two
molecul
interest
discuss
sialyl
oligosaccharid
carnitin
metabol
tie
mitochondri
homeostasi
long
studi
context
sever
infect
septic
patient
show
mani
abnorm
lipid
metabol
includ
deplet
cellular
level
reduct
plasma
level
increas
urinari
three
recent
metabolom
studi
also
found
increas
urinari
concentr
patient
bacteri
inde
pneumococc
cytotoxin
pneumolysin
caus
mitochondri
damag
may
account
observ
disarray
lipid
sialyl
oligosaccharid
broken
digest
lysosom
rel
increas
sialyl
oligosaccharid
cours
bacteri
infect
may
repres
transient
lysosom
dysfunct
inde
role
lysosom
human
health
diseas
start
unveil
evid
alreadi
accumul
lysosom
serv
regul
macrophag
key
effector
pneumonia
intracellular
recent
transcriptom
studi
also
show
messeng
rna
pathway
associ
lysosom
function
among
profoundli
disrupt
cours
human
short
studi
point
organel
dysfunct
crucial
discrimin
bacteri
viral
infect
viral
pneumonia
associ
increas
urin
concentr
end
product
collagen
metabol
substrat
enzym
prolidas
promot
surfac
express
receptor
target
viral
higher
urinari
level
found
studi
may
therefor
reflect
impair
prolidas
activ
could
expect
cours
viral
infect
although
analyt
method
chemometr
data
process
method
use
studi
weak
import
concern
fact
collect
sampl
patient
constitut
verit
sourc
bia
issu
could
avoid
collect
urin
sampl
children
present
emerg
depart
respiratori
symptom
fever
analyz
obtain
children
actual
enrol
studi
worth
bear
mind
futur
metabolom
studi
conduct
acut
care
set
anoth
weak
studi
concern
small
number
patient
two
group
may
limit
valid
find
hand
adopt
stringent
enrol
criteria
conserv
diagnost
algorithm
ensur
two
group
etiolog
pure
thu
enhanc
specif
find
potenti
limit
exploratori
studi
lie
lack
extern
valid
set
test
model
could
valid
intern
mean
stabil
select
ensur
reliabl
find
emerg
data
collect
though
preliminari
studi
present
find
seem
promis
start
point
conduct
larger
valid
studi
conclus
metabolom
analysi
urin
sampl
collect
children
cap
differ
etiolog
provid
new
insight
multipl
discret
pathophysiolog
pathway
involv
reveal
put
biomark
consider
clinic
valu
pneumococc
cap
prompt
stronger
activ
hpa
axi
mark
organel
dysfunct
rel
increas
cgmp
significantli
derang
amino
acid
metabol
viral
cap
hand
reduc
prolidas
activ
impair
macrophag
activ
confirm
larger
studi
find
may
implic
possibl
prompt
use
rapid
diagnosi
manag
pneumococc
cap
author
declar
conflict
interest
